Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced the risk of death by 67%.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
Researchers Characterize Gut Microbiome of Patients With mRCC and Sarcopenia
Sarcopenic patients with metastatic renal cell carcinoma have distinct bacterial populations that express metabolic pathways associated with a catabolic state.
Live Bacterial Product Improves Outcomes in Metastatic Renal Cell Carcinoma
CBM588, a live bacterial product, improves the efficacy of first-line treatment with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma, a study suggests.
RCC Trials Use “Potentially Excessive” Exclusion Criteria
Renal cell carcinoma trials conducted in the past 10 years used exclusion criteria deemed potentially excessive by ASCO and FCR.
Characteristics of Renal Cell Carcinoma Differ According to Genetic Ancestry
Among patients with renal cell carcinoma, clinical presentation, extent of disease, and germline and somatic alterations differ according to genetic ancestry.
Lenvatinib Plus Pembrolizumab Improves PFS2, OS in Advanced Renal Cell Carcinoma
Second progression-free survival is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.
Intratumoral Vaccination Does Not Appear to Benefit Patients With mRCC
Adding ilixadencel to treatment with sunitinib does not appear to improve outcomes in patients with metastatic renal cell carcinoma undergoing nephrectomy.
RCC With NF2 Mutations Associated With Metastatic Disease, Poor Survival
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Immunotherapy Combos Overtake TKI Monotherapy as First-Line Treatment for mRCC
Immunotherapy-based combinations have overtaken TKI monotherapy as the most-used first-line treatment for mRCC in US oncology clinics, a study suggests.
Tivozanib Improves Long-Term PFS in Rel/Ref Metastatic Renal Cell Carcinoma
Tivozanib improves long-term progression-free survival, when compared with sorafenib, in patients with relapsed or refractory metastatic renal cell carcinoma, an analysis suggests.
Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab
Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.
RCC Patients Have 10-Fold Higher Risk of End-Stage Renal Disease
The risk for end-stage renal disease is 10 times higher in patients with renal cell carcinoma than in the general population, a study suggests.
AUA Surveillance Guidelines May Improve Metastasis-Free Survival
Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.
Ipi-Nivo and Axi-Pembro Produce Similar OS as Frontline Therapy in Metastatic RCC
Real-world data suggest similar overall survival outcomes with frontline ipilimumab-nivolumab or axitinib-pembrolizumab in patients with metastatic renal cell carcinoma.
Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Bevacizumab Biosimilar Alymsys Now Available
Alymsys (bevacizumab-maly), a biosimilar to Avastin (bevacizumab), has been made available by Amneal Pharmaceuticals.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
T1a RCC Death Risk Higher After Ablation vs Partial Nephrectomy
The study included a large, contemporary cohort of patients with T1a renal cell carcinoma undergoing partial nephrectomy or local tumor destruction.
Real-World Data Support Nivolumab + Ipilimumab for First-Line mRCC Therapy
A real-world study revealed an objective response rate consistent with that observed in the CheckMate 214 trial.
Follow-Up Confirms DFS Benefit With Pembrolizumab in Clear Cell RCC
Adjuvant pembrolizumab could be a new standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, according to researchers.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...